Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MPI | P34949 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29764890 | 1.00 | HTT (0.49) | HTTMAPTPKMLMNAKMT2A | |
| SCHEMBL15544876 | 0.81 | ATM (0.41) | HTTMAPTPKMLMNAKMT2A | |
| SCHEMBL15544875 | 0.81 | ATM (0.41) | HTTMAPTPKMLMNAKMT2A | |
| SCHEMBL29865611 | 0.81 | HTT (0.50) | HTTMAPTPKMLMNAKMT2A | |
| SCHEMBL2207311 | 0.81 | HTT (0.50) | HTTMAPTPKMLMNAKMT2A | |
| SCHEMBL29701749 | 0.79 | HTT (0.49) | HTTMAPTPKMLMNAKMT2A | |
| SCHEMBL6073752 | 0.79 | HTT (0.49) | HTTMAPTPKMLMNAKMT2A | |
| SCHEMBL17631174 | 0.79 | HTT (0.49) | HTTMAPTPKMLMNAKMT2A | |
| SCHEMBL3648669 | 0.79 | ERN1 (0.50) | HTTMAPTPKMLMNAKMT2A | |
| SCHEMBL3586217 | 0.79 | HTT (0.57) | HTTMAPTPKMLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606544-B2 | JAK1 selective kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| US-12595245-B2 | Inhibitors of MET kinase | CELYN THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| EP-4558505-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-3956322-B1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2006112828-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006099410-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006093832-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS INC. | 2005-12-29 | — | — | US | disclosed |
| US-4273706-A | Nondiffusible heterocyclylazonaphthol dye-releasing compounds | EASTMAN KODAK COMPANY (US) | 1981-06-16 | — | — | US | disclosed |
| US-4207104-A | DIFFUSION TRANSFER TO FORM METALLIZED DYE IMAGE OF EXCELLENT STABILITY | EASTMAN KODAK COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
| US-4204870-A | METALLIZED DYES | EASTMAN KODAK COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | HTT 3330/4885MAPT 3268/4885PKM 2586/4885 |
| US-12595245-B2 | Inhibitors of MET kinase | MET, ABL1, ERBB2 | HTT 4072/4885MAPT 2891/4885PKM 1074/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | HTT 4306/4885MAPT 4795/4885PKM 4464/4885 |
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | HTT 3328/4885MAPT 2493/4885PKM 301/4885 |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | HTT 3330/4885MAPT 3268/4885PKM 2586/4885 |
| US-12606544-B2 | JAK1 selective kinase inhibitor | JAK1, JAK2, JAK3 | HTT 4703/4885MAPT 4828/4885PKM 2979/4885 |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | CCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MALT1 | HTT 2638/4885MAPT 4875/4885PKM 4382/4885 |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK3 | HTT 4166/4885MAPT 1615/4885PKM 1525/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | HTT 163/4885MAPT 3496/4885PKM 3219/4885 |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | HTT 871/4885MAPT 2434/4885PKM 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.